CBIO

Rating neutralAI Memo

Crescent Biopharma

As of 2026-09-24/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Initial ASCEND proof-of-concept data • 2027-03-31

Base target: $15 / p=45% prob

Biggest risk

The programs remain clinical-stage, and early data may be inconclusive or disappointing. Second-quarter R&D expense rose to $19.4 million from $12.1 million a year earlier; further trial expansion could increase spending. [#SEC-8K-2026-07-30] SEC earnings exhibit.

Invalidation

Break below $7 or thesis failure.

What would change my mind?

The July financing provides management-estimated runway into the second half of 2028, while separate CR-001 and CR-003 readouts begin in Q1 2027. Convincing safety and activity could support a substantial re-rating. [#SEC-8K-2026-07-30] SEC earnings exhibit.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-09-24

Base target

$15

p=45%

Bull target

$26

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

CR-002 global trial initiation
CR-001 combination data
The July financing provides management-estimated runway into the second half of 2028, while separate CR-001 and CR-003 readouts begin in Q1 2027.

BearKey bullets

CR-002 trial initiation and 2027 data timing could slip; completion of the earlier IND target is unconfirmed in the supplied evidence.
China studies rely on Kelun-Biotech execution; collaboration does not remove clinical or regulatory risk.
Initial oncology readouts are early-stage; safety, response durability or cohort composition may fall short of expectations.

WatchKey bullets

Initial ASCEND proof-of-concept data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $15 (p=45%)

Target spread vs base: +73% / -53%

Scenario probabilities

Bull Target: $26 (p=25%)Base Target: $15 (p=45%)Bear Target: $7 (p=30%)

Commentary

The company-confirmed pipeline timetable and extended runway improve milestone visibility, but the deterministic prior remains directionally neutral and decisive clinical data are pending. The packet does not establish a reliable recent price reaction, analyst revision trend, or sufficient social and options coverage; the zero-valued sentiment fields above denote unavailable measurements, not neutral observations. The September third-party article is not treated as company confirmation.

As of 2026-09-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

CR-002 global trial initiation
CR-001 combination data

Scenarios

Bull Target (Scenario probability)

$26 / p=25% prob

Base Target (Scenario probability)

$15 / p=45% prob

Bear Target (Scenario probability)

$7 / p=30% prob

Analysis 2026-09-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-03-31
Initial ASCEND proof-of-concept data
Crescent expects first-quarter 2027 CR-001 data covering safety, pharmacology and preliminary antitumor activity across solid-tumor cohorts. Clinical interpretation, rather than enrollment progress alone, is the principal near-term valuation test. [#SEC-8K-2026-07-30] SEC earnings exhibit.
Prob 55.00% • Move 35.00% • Priced-in 25.00%
EVENT2027-03-31
CR-003 initial clinical data
Kelun-Biotech's China Phase 1/2 trial of the ITGB6-targeted ADC CR-003 is ongoing, with proof-of-concept data expected in the first quarter of 2027. The readout offers a distinct pipeline test but remains early-stage and partner-executed. [#SEC-8K-2026-07-30] SEC earnings exhibit.
Prob 50.00% • Move 22.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

CR-002 global trial initiation
2026-12-31
Crescent said its global Phase 1/2 trial of the PD-L1-targeted ADC CR-002 was on track to begin in the second half of 2026. The earlier mid-2026 IND target is not confirmed as completed in the supplied evidence; trial initiation is the milestone to verify. [#8-K-2026-07-30] [#SEC-8K-2026-07-30] SEC earnings exhibit.
Prob 60% • Move 10% • Priced-in 45%

Long-term Catalysts

Months to a year

CR-001 combination data
2027-09-30
Crescent anticipates initial CR-001 plus standard-of-care chemotherapy data and initial China Phase 2 CR-001 plus sac-TMT data around mid-2027. Safety and response findings could broaden or weaken the case for CR-001 combinations. [#SEC-8K-2026-07-30] SEC earnings exhibit.
Prob 45% • Move 30% • Priced-in 15%

Risks

CR-002 trial initiation and 2027 data timing could slip; completion of the earlier IND target is unconfirmed in the supplied evidence.
China studies rely on Kelun-Biotech execution; collaboration does not remove clinical or regulatory risk.
Initial oncology readouts are early-stage; safety, response durability or cohort composition may fall short of expectations.
Rising clinical R&D costs and the July share issuance create spending and dilution risk despite the stated cash runway. [#SEC-8K-2026-07-30] SEC earnings exhibit.

Peers

Symbol	Summary
TECX	Similar small-cap biotechnology market-cap range in the packet, but not a validated same-indication or same-modality oncology peer; useful chiefly for financing and clinical-event risk context.
SGMT	Similar market-cap range and development-stage biotechnology exposure, but disease and program differences make it a loose valuation comparator.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-24

Loading AI feed…

Symbol

Summary

TECX

Similar small-cap biotechnology market-cap range in the packet, but not a validated same-indication or same-modality oncology peer; useful chiefly for financing and clinical-event risk context.

SGMT

Similar market-cap range and development-stage biotechnology exposure, but disease and program differences make it a loose valuation comparator.